Ron Cohen Acorda Therapeutics CEO Rating

Acorda Therapeutics CEO Ron Cohen Bio

Dr. Ron Cohen, M.D., has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer and President since 1995. Dr. Cohen served as Principal in the startup of Advanced Tissue Sciences, Inc. He served as the Chairman Emeritus of the New York Biotechnology Association and served as its Chairman and Director. Dr. Cohen serves as the Chairman of Emerging Company Section at the (Biotechnology Innovation Organization) also known as Biotechnology Industry Organization (BIO). He served as the Chairman of Acorda Therapeutics, Inc. and has been its Director since 1995. Dr. Cohen serves as a Director of Zymenex A/S, a Danish pharmaceutical company and Biotechnology Industry Organization (BIO). He served as a Director of Dyax Corp. from November 2011 to January 22, 2016. He also serves on the Scientific Advisory Board of the Daniel Heumann Fund and as a member of the Columbia-Presbyterian Health Sciences Advisory Council. He serves on the Advisory Editorial Board of BioPeople magazine and as a member of the Columbia-Presbyterian Health Sciences Council. He has been a Non-Executive Director at Vascular Biogenics Ltd. since February 11, 2015. He has been a Director of Biotie Therapies Corp. since May 11, 2016. He served as a Director at Ceregene, Inc. He received his B.A. degree with honors in Psychology from Princeton University and his M.D from the Columbia College of Physicians & Surgeons. Dr. Cohen completed a residency in Internal Medicine at the University of Virginia Medical Center and is Board Certified in Internal Medicine.

Acorda Therapeutics CEO Ron Cohen At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Acorda Therapeutics.

Based on 5 ratings, Ron Cohen ranks right below Idera Pharmaceuticals' CEO, Vincent Milano.

Overall, the CEO score has remained stable over the last 90 days.